$IGMS
IGM Biosciences, Inc.

2023 Q1 Form 10-Q Financial Statement

#000095017023021521 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $522.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.00M $13.08M
YoY Change -0.6% 60.9%
% of Gross Profit
Research & Development $50.89M $38.88M
YoY Change 30.92% 64.92%
% of Gross Profit
Depreciation & Amortization $1.664M $1.224M
YoY Change 35.95% 81.87%
% of Gross Profit
Operating Expenses $63.90M $51.96M
YoY Change 22.98% 63.87%
Operating Profit -$63.37M -$51.96M
YoY Change 21.98% 63.87%
Interest Expense $4.172M $54.00K
YoY Change 7625.93%
% of Operating Profit
Other Income/Expense, Net $4.152M $62.00K
YoY Change 6596.77% 0.0%
Pretax Income -$59.22M -$51.89M
YoY Change 14.12% 64.01%
Income Tax $87.00K $0.00
% Of Pretax Income
Net Earnings -$59.31M -$51.89M
YoY Change 14.29% 63.99%
Net Earnings / Revenue -11361.88%
Basic Earnings Per Share -$1.33 -$1.53
Diluted Earnings Per Share -$1.33 -$1.530M
COMMON SHARES
Basic Shares Outstanding 44.47M 33.84M
Diluted Shares Outstanding 44.47M 33.84M

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $373.4M $187.5M
YoY Change 99.18% -43.48%
Cash & Equivalents $140.2M $75.42M
Short-Term Investments $233.2M $112.0M
Other Short-Term Assets $11.36M $10.35M
YoY Change 9.79% 8.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $384.8M $197.8M
YoY Change 94.51% -42.02%
LONG-TERM ASSETS
Property, Plant & Equipment $36.73M $29.98M
YoY Change 22.5% 16.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.157M $1.007M
YoY Change 114.2% 13.66%
Total Long-Term Assets $77.99M $59.93M
YoY Change 30.12% 52.41%
TOTAL ASSETS
Total Short-Term Assets $384.8M $197.8M
Total Long-Term Assets $77.99M $59.93M
Total Assets $462.7M $257.7M
YoY Change 79.54% -32.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.972M $4.011M
YoY Change -0.97% -29.63%
Accrued Expenses $29.64M $19.30M
YoY Change 53.54% 231.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.63M $27.37M
YoY Change 59.43% 84.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $179.7M $25.85M
YoY Change 594.98% 158.54%
Total Long-Term Liabilities $179.7M $25.85M
YoY Change 594.98% 158.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.63M $27.37M
Total Long-Term Liabilities $179.7M $25.85M
Total Liabilities $223.3M $53.22M
YoY Change 319.59% 114.05%
SHAREHOLDERS EQUITY
Retained Earnings -$634.1M -$405.6M
YoY Change 56.34% 84.2%
Common Stock $873.5M $610.0M
YoY Change 43.19% 5.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $239.4M $204.5M
YoY Change
Total Liabilities & Shareholders Equity $462.7M $257.7M
YoY Change 79.54% -32.26%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$59.31M -$51.89M
YoY Change 14.29% 63.99%
Depreciation, Depletion And Amortization $1.664M $1.224M
YoY Change 35.95% 81.87%
Cash From Operating Activities -$51.00M -$38.87M
YoY Change 31.2% 37.53%
INVESTING ACTIVITIES
Capital Expenditures $3.937M $2.977M
YoY Change 32.25% -50.98%
Acquisitions
YoY Change
Other Investing Activities $73.76M -$16.15M
YoY Change -556.84% -135.35%
Cash From Investing Activities $69.82M -$19.12M
YoY Change -465.13% -148.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.00K 72.00K
YoY Change 4.17% -235.85%
NET CHANGE
Cash From Operating Activities -51.00M -38.87M
Cash From Investing Activities 69.82M -19.12M
Cash From Financing Activities 75.00K 72.00K
Net Change In Cash 18.90M -57.92M
YoY Change -132.63% -612.75%
FREE CASH FLOW
Cash From Operating Activities -$51.00M -$38.87M
Capital Expenditures $3.937M $2.977M
Free Cash Flow -$54.93M -$41.85M
YoY Change 31.28% 21.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001496323
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39045
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
IGM Biosciences, Inc.
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0349194
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
325 E. Middlefield Road
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
146195000
CY2023Q1 us-gaap Liabilities
Liabilities
223312000
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Mountain View
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94043
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
965-7873
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
IGMS
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140164000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121231000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
658000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
689000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
233232000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
305931000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10702000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10570000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
384756000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
438421000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36731000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33484000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39098000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39591000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2157000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2003000
CY2023Q1 us-gaap Assets
Assets
462742000
CY2022Q4 us-gaap Assets
Assets
513499000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3972000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2512000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29637000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33621000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6426000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5816000
CY2023Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
3597000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2736000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43632000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44685000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34868000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35356000
CY2023Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
144812000
CY2022Q4 us-gaap Liabilities
Liabilities
226236000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
354000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11047000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-59309000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
873480000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
862359000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-347000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-701000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-634135000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-574826000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
239430000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
287263000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462742000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
513499000
CY2023Q1 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
522000
CY2022Q1 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50894000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38875000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13002000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13081000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
63896000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
51956000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-63374000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-51956000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4172000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
54000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4152000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59222000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51894000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-59309000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-51894000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44466764
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44466764
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33838895
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33838895
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-59309000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-51894000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
354000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58955000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52021000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
287263000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18902000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
239430000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
244908000
CY2022Q1 igms Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
133000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11499000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-51894000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
204519000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-59309000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-51894000
CY2023Q1 us-gaap Depreciation
Depreciation
1664000
CY2022Q1 us-gaap Depreciation
Depreciation
1224000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11047000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11499000
CY2023Q1 igms Purchase Net Discount Premium On Marketable Securities
PurchaseNetDiscountPremiumOnMarketableSecurities
-1705000
CY2022Q1 igms Purchase Net Discount Premium On Marketable Securities
PurchaseNetDiscountPremiumOnMarketableSecurities
20000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2487000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-165000
CY2023Q1 igms Non Cash Lease Expense
NonCashLeaseExpense
1323000
CY2022Q1 igms Non Cash Lease Expense
NonCashLeaseExpense
1001000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
58000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-933000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
154000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-29000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1604000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1244000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5102000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
362000
CY2023Q1 igms Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-708000
CY2022Q1 igms Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-944000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-522000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50997000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38889000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3937000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2977000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
89274000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40126000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
163035000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69824000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19103000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
133000
CY2023Q1 igms Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
0
CY2022Q1 igms Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
-61000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-57920000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121920000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
134035000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140822000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76115000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140164000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75417000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
658000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
698000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140822000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76115000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
830000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2093000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2439000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
231000
CY2023Q1 igms Issuance Costs For Public Offerings In Accounts Payable And Accrued Liabilities
IssuanceCostsForPublicOfferingsInAccountsPayableAndAccruedLiabilities
0
CY2022Q1 igms Issuance Costs For Public Offerings In Accounts Payable And Accrued Liabilities
IssuanceCostsForPublicOfferingsInAccountsPayableAndAccruedLiabilities
460000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-634100000
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
373400000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such management estimates include, but are not limited to, those related to revenue recognition, marketable securities, manufacturing accruals, accrued research and development expenses, stock-based compensation, operating lease right-of-use (ROU) assets and liabilities, income tax uncertainties and the valuation of deferred tax assets. The Company bases its estimates on its historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to revenue recognition, accrued research and development costs, and leases.</span></p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company invests in money market funds, U.S. treasury securities, corporate bonds, commercial paper, and U.S. government agency securities. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers to the extent recorded on the balance sheets. The Company’s investment policy limits investments to high credit quality securities issued by the U.S. government and its agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company has not experienced any material losses on its deposits of cash, cash equivalents, and marketable securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company’s early stages of clinical drug development; uncertainties related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; the Company’s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company’s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company’s ability to enroll patients in its ongoing and future clinical trials; the Company’s ability to successfully manufacture and supply its product candidates for clinical trials; the occurrence of any event or circumstance that could give rise to the termination of the Company’s collaborations with third parties; the Company’s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company’s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company’s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s product candidates will require approvals from the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></p>
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
253829000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
716000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
54
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
69
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
716000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company’s results of operations or financial position as of March 31, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
CY2023Q1 igms Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
370101000
CY2023Q1 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
56000
CY2023Q1 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
403000
CY2023Q1 igms Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
369754000
CY2022Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
420550000
CY2022Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2022Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
716000
CY2022Q4 igms Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
419849000
CY2023Q1 igms Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
0
CY2022Q4 igms Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
0
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
196354000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
403000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
196354000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
403000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
253829000
CY2023Q1 us-gaap Interest Receivable
InterestReceivable
600000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
500000
CY2023Q1 igms Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
19144000
CY2022Q4 igms Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
20747000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2728000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1759000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7402000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
10920000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
363000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
195000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29637000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33621000
CY2020Q4 igms Minimum Notice Term To Increase Or Decrease Holding Percentage Of Pre Funded Warrants
MinimumNoticeTermToIncreaseOrDecreaseHoldingPercentageOfPreFundedWarrants
P61D
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock (excluding non-voting common stock) is entitled to one vote.
CY2023Q1 igms Number Of Voting Rights For Each Common Stock Held
NumberOfVotingRightsForEachCommonStockHeld
1
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q1 igms Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
5972087
CY2022Q4 igms Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
5802317
CY2023Q1 igms Restricted Stock Units
RestrictedStockUnits
350814
CY2022Q4 igms Restricted Stock Units
RestrictedStockUnits
401180
CY2023Q1 igms Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
2808852
CY2022Q4 igms Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
1310601
CY2023Q1 igms Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
1539855
CY2022Q4 igms Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
1109032
CY2023Q1 igms Pre Funded Warrants
PreFundedWarrants
1334332
CY2022Q4 igms Pre Funded Warrants
PreFundedWarrants
1334332
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12005940
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9957462
CY2020Q4 igms Maximum Allowed Holding Percentage Of Shares After Exercise Of Warrants
MaximumAllowedHoldingPercentageOfSharesAfterExerciseOfWarrants
0.0999
CY2020Q4 igms Maximum Allowed Combined Voting Percentage Of Shares After Exercise Of Warrants
MaximumAllowedCombinedVotingPercentageOfSharesAfterExerciseOfWarrants
0.0999
CY2020Q4 igms Maximum Allowed Percentage Of Pre Funded Warrants To Exercise
MaximumAllowedPercentageOfPreFundedWarrantsToExercise
0.1999
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
148931000
CY2023Q1 igms Deferred Revenue Addition
DeferredRevenueAddition
0
CY2023Q1 igms Deferred Revenue Deduction
DeferredRevenueDeduction
-522000
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
148409000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023Q1 igms Contract With Customer Assets
ContractWithCustomerAssets
0
CY2022Q1 igms Contract With Customer Assets
ContractWithCustomerAssets
0
CY2023Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0
CY2023Q1 igms Income Tax Provision
IncomeTaxProvision
100000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2022Q1 igms Income Tax Provision
IncomeTaxProvision
0
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
150000000.0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6381152
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6270227

Files In Submission

Name View Source Status
igms-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
igms-20230331_def.xml Edgar Link unprocessable
igms-20230331_lab.xml Edgar Link unprocessable
0000950170-23-021521-index-headers.html Edgar Link pending
0000950170-23-021521-index.html Edgar Link pending
0000950170-23-021521.txt Edgar Link pending
0000950170-23-021521-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
igms-20230331.htm Edgar Link pending
igms-20230331.xsd Edgar Link pending
igms-ex31_1.htm Edgar Link pending
igms-ex31_2.htm Edgar Link pending
igms-ex32_1.htm Edgar Link pending
igms-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
igms-20230331_pre.xml Edgar Link unprocessable
igms-20230331_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending